860 SYNERGISTIC ANTITUMORAL EFFECT OF SUBCUTANEOUS INOCULATION WITH AFP-PULSED DC COMBINED WITH INTRATUMORAL INJECTION OF CD40L-EXPRESSING DC IN ESTABLISHED HEPATOCELLULAR TUMORS (HCC) IN VIVO

Results:1.The cumulative probability of non-bleeding (CP) in FHC group (29 cases) wais significantly higher than placebo group (27 cases; 96.6% vs. 76.3%,P = 0.028) in 56 patients with small varices.2. In 90 patients with moderate and severe varices but without history of bleeding, CP was 84.8% in FHCCP group (30 cases), 64.8% in FHC group (30 cases), and 0% in propranolol group (30 cases).There is obvious difference between FHCCP group and propranolol group (P = 0.013).The bleeding risk in propranolol group is 4.065 times compared with FHCCP group.3.In 35 patients with history of esophageal variceal bleeding, both CP and the median time of non-bleeding in FHCCP group (18 cases) were significantly higher than that of propranolol group (17 cases; CP: 44% vs. 24.2%,P = 0.035; the median time of non-bleeding: 40.00±17.92months vs. 7.00±2.35months).The bleeding risk in propranolol group is 2.474 times compared with FHCCP group.Conclusions: FHC can increase CP in cirrhotic patients with small varices.Whatever having the history of esophageal variceal bleeding, FHCCP can increase CP in cirrhotic patients with moderate and severe varices.03a.